168 related articles for article (PubMed ID: 32972342)
1. Unveiling the Potential of Purinergic Signaling in Schistosomiasis Treatment.
Oliveira NF; Silva CLM
Curr Top Med Chem; 2021; 21(3):193-204. PubMed ID: 32972342
[TBL] [Abstract][Full Text] [Related]
2. Purinergic signaling in schistosomal infection.
Silva CLM
Biomed J; 2016 Oct; 39(5):316-325. PubMed ID: 27884378
[TBL] [Abstract][Full Text] [Related]
3. P2Y
Oliveira NF; Monteiro MMLV; Mainieri NS; Tamura AS; Pereira LM; Crepaldi LD; Coutinho-Silva R; Savio LEB; Silva CLM
Front Immunol; 2023; 14():1328897. PubMed ID: 38239348
[TBL] [Abstract][Full Text] [Related]
4. Increased expression of NTPDases 2 and 3 in mesenteric endothelial cells during schistosomiasis favors leukocyte adhesion through P2Y1 receptors.
Oliveira SD; Oliveira NF; Meyer-Fernandes JR; Savio LE; Ornelas FG; Ferreira ZS; Coutinho-Silva R; Silva CL
Vascul Pharmacol; 2016 Jul; 82():66-72. PubMed ID: 26924460
[TBL] [Abstract][Full Text] [Related]
5. Purine Release, Metabolism, and Signaling in the Inflammatory Response.
Linden J; Koch-Nolte F; Dahl G
Annu Rev Immunol; 2019 Apr; 37():325-347. PubMed ID: 30676821
[TBL] [Abstract][Full Text] [Related]
6. Purinergic signaling in kidney disease.
Menzies RI; Tam FW; Unwin RJ; Bailey MA
Kidney Int; 2017 Feb; 91(2):315-323. PubMed ID: 27780585
[TBL] [Abstract][Full Text] [Related]
7. Eosinophils and Purinergic Signaling in Health and Disease.
Ferrari D; Vuerich M; Casciano F; Longhi MS; Melloni E; Secchiero P; Zech A; Robson SC; Müller T; Idzko M
Front Immunol; 2020; 11():1339. PubMed ID: 32733449
[TBL] [Abstract][Full Text] [Related]
8. P2 purinergic receptors signal to STAT3 in astrocytes: Difference in STAT3 responses to P2Y and P2X receptor activation.
Washburn KB; Neary JT
Neuroscience; 2006 Oct; 142(2):411-23. PubMed ID: 16905269
[TBL] [Abstract][Full Text] [Related]
9. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
10. ATP induces contraction of cultured brain capillary pericytes via activation of P2Y-type purinergic receptors.
Hørlyck S; Cai C; Helms HCC; Lauritzen M; Brodin B
Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H699-H712. PubMed ID: 33306443
[TBL] [Abstract][Full Text] [Related]
11. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
12. Molecular Context of ADP-ribosylation in Schistosomes for Drug Discovery and Vaccine Development.
Chutshela A; Masamba P; Oyinloye BE; Kappo AP
Curr Drug Discov Technol; 2021; 18(4):473-484. PubMed ID: 32767945
[TBL] [Abstract][Full Text] [Related]
13. Target-based molecular modeling strategies for schistosomiasis drug discovery.
Ferreira LG; Oliva G; Andricopulo AD
Future Med Chem; 2015; 7(6):753-64. PubMed ID: 25996068
[TBL] [Abstract][Full Text] [Related]
14. Interplay between P2Y(1), P2Y(12), and P2X(1) receptors in the activation of megakaryocyte cation influx currents by ADP: evidence that the primary megakaryocyte represents a fully functional model of platelet P2 receptor signaling.
Tolhurst G; Vial C; Léon C; Gachet C; Evans RJ; Mahaut-Smith MP
Blood; 2005 Sep; 106(5):1644-51. PubMed ID: 15914557
[TBL] [Abstract][Full Text] [Related]
15. The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.
Antonioli L; Blandizzi C; Pacher P; Haskó G
Pharmacol Rev; 2019 Jul; 71(3):345-382. PubMed ID: 31235653
[TBL] [Abstract][Full Text] [Related]
16. Purinergic receptors and the inflammatory response mediated by lipids.
Alarcón-Vila C; Pizzuto M; Pelegrín P
Curr Opin Pharmacol; 2019 Aug; 47():90-96. PubMed ID: 30952060
[TBL] [Abstract][Full Text] [Related]
17. Purinergic receptors mediate endothelial dysfunction and participate in atherosclerosis.
Wu XM; Zhang N; Li JS; Yang ZH; Huang XL; Yang XF
Purinergic Signal; 2023 Mar; 19(1):265-272. PubMed ID: 34981330
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of purinergic receptors and their effects on proliferation and induction of neuronal differentiation of P19 embryonal carcinoma cells.
Resende RR; Britto LR; Ulrich H
Int J Dev Neurosci; 2008 Nov; 26(7):763-77. PubMed ID: 18675894
[TBL] [Abstract][Full Text] [Related]
19. The platelet ATP and ADP receptors.
Oury C; Toth-Zsamboki E; Vermylen J; Hoylaerts MF
Curr Pharm Des; 2006; 12(7):859-75. PubMed ID: 16515502
[TBL] [Abstract][Full Text] [Related]
20. Agonists and Antagonists for Purinergic Receptors.
Müller CE; Baqi Y; Namasivayam V
Methods Mol Biol; 2020; 2041():45-64. PubMed ID: 31646479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
